Your browser doesn't support javascript.
loading
Identification of an H-Ras nanocluster disrupting peptide.
Steffen, Candy Laura; Manoharan, Ganesh Babu; Pavic, Karolina; Yeste-Vázquez, Alejandro; Knuuttila, Matias; Arora, Neha; Zhou, Yong; Härmä, Harri; Gaigneaux, Anthoula; Grossmann, Tom N; Abankwa, Daniel Kwaku.
Afiliação
  • Steffen CL; Cancer Cell Biology and Drug Discovery group, Department of Life Sciences and Medicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
  • Manoharan GB; Cancer Cell Biology and Drug Discovery group, Department of Life Sciences and Medicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
  • Pavic K; Cancer Cell Biology and Drug Discovery group, Department of Life Sciences and Medicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
  • Yeste-Vázquez A; Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Amsterdam, The Netherlands.
  • Knuuttila M; Amsterdam Institute of Molecular and Life Sciences (AIMMS), VU University Amsterdam, Amsterdam, The Netherlands.
  • Arora N; Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland.
  • Zhou Y; Department of Integrative Biology and Pharmacology, McGovern Medical School, UT Health, Houston, TX, 77030, USA.
  • Härmä H; Department of Integrative Biology and Pharmacology, McGovern Medical School, UT Health, Houston, TX, 77030, USA.
  • Gaigneaux A; Chemistry of Drug Development, Department of Chemistry, University of Turku, 20500, Turku, Finland.
  • Grossmann TN; Bioinformatics Core, Department of Life Sciences and Medicine, University of Luxembourg, 4367, Esch-sur-Alzette, Luxembourg.
  • Abankwa DK; Department of Chemistry and Pharmaceutical Sciences, VU University Amsterdam, Amsterdam, The Netherlands.
Commun Biol ; 7(1): 837, 2024 Jul 09.
Article em En | MEDLINE | ID: mdl-38982284
ABSTRACT
Hyperactive Ras signalling is found in most cancers. Ras proteins are only active in membrane nanoclusters, which are therefore potential drug targets. We previously showed that the nanocluster scaffold galectin-1 (Gal1) enhances H-Ras nanoclustering via direct interaction with the Ras binding domain (RBD) of Raf. Here, we establish that the B-Raf preference of Gal1 emerges from the divergence of the Raf RBDs at their proposed Gal1-binding interface. We then identify the L5UR peptide, which disrupts this interaction by binding with low micromolar affinity to the B- and C-Raf-RBDs. Its 23-mer core fragment is sufficient to interfere with H-Ras nanoclustering, modulate Ras-signalling and moderately reduce cell viability. These latter two phenotypic effects may also emerge from the ability of L5UR to broadly engage with several RBD- and RA-domain containing Ras interactors. The L5UR-peptide core fragment is a starting point for the development of more specific reagents against Ras-nanoclustering and -interactors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos Limite: Humans Idioma: En Revista: Commun Biol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Luxemburgo

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos Limite: Humans Idioma: En Revista: Commun Biol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Luxemburgo